OpenAI is exploring a major expansion into consumer health, signaling one of its most ambitious moves beyond AI infrastructure and into a deeply complex, legacy-heavy industry. While the company has not confirmed any specific product plans, sources familiar with the matter say OpenAI is actively evaluating opportunities such as a personal health assistant or a health data aggregator. The effort is being led by Nate Gross, who joined OpenAI in June as head of healthcare strategy after co-founding Doximity, a leading health tech platform. Two months later, OpenAI brought on Ashley Alexander, former vice president of health products at Instagram, to help shape its health product vision. The company’s growing interest in healthcare comes amid rising demand for AI-driven health tools. With around 800 million weekly active users, ChatGPT has become a go-to source for health-related questions, according to industry observers. This user behavior has caught the attention of investors and healthcare leaders, who see a unique opportunity for OpenAI to solve a problem that has stymied Big Tech for years: creating a truly useful, patient-owned personal health record. Despite decades of effort by companies like Google, Apple, and Microsoft, consumer health data remains fragmented. Apple’s Health Records feature, for example, requires hospitals to opt in and patients to manually connect their data. Google’s past health initiatives were abandoned or derailed by privacy concerns, and Microsoft’s HealthVault was shut down in 2019 after failing to gain traction. The core issue has been friction—users are reluctant to jump through multiple hoops to access their own medical information. A recent federal rule banning “information blocking” has helped break down some of these barriers, making it easier for patients to request and receive their health data. However, enforcement remains inconsistent, and many hospitals still limit what can be downloaded. Intermediaries like Health Gorilla and Particle Health have emerged to help pull data from multiple sources, clean it, and share it securely with apps—offering a potential model for OpenAI to follow. Rather than building a direct health record system from scratch, OpenAI may instead focus on creating an ecosystem. Gross has emphasized the importance of partnerships, suggesting that OpenAI’s greatest impact could come through collaboration with health tech companies, labs, and providers. Potential partners include consumer lab testing firms like Superpower and Function Health, which could feed data into AI-powered tools. OpenAI is also already working with major pharmaceutical companies like Eli Lilly and Sanofi on drug discovery, and with health tech firms such as Penda Health on clinical decision support. These enterprise partnerships suggest a broader strategy: using AI to improve healthcare delivery at multiple levels, from research to patient care. While OpenAI has not encouraged users to upload medical records, it has made clear that its models should not be used for diagnosis or treatment. Still, the company’s recent updates to its usage policies were misinterpreted by some as a ban on health advice—this was not the case. OpenAI’s health AI research lead confirmed the models remain capable of providing general medical information. With its massive user base, deep AI expertise, and aggressive growth strategy, OpenAI is seen by many investors as a serious contender in health tech—potentially more capable than past Big Tech entrants. As healthcare becomes increasingly digitized and AI-driven, OpenAI’s next moves could reshape how consumers interact with their health data and care.